BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of $51.00 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-07-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2012-07-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $51.00M, a 104.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $27.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was -$763.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $107.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2011 was -$674.00M, a 496.47% decline from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2010 was $170.00M, a 4.49% decline from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2009 was $178.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2008 was -$1.26B, a 783.70% decline from fiscal 2007.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-06-30 | $51.00M 10-Q · filed 2012-07-25 | $78.00M 10-Q · filed 2012-07-25 | -$685.00M derived: sum of 3 quarters · filed 2012-07-25 | -$578.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2012-03-31 | $27.00M 10-Q · filed 2012-04-26 | -$736.00M derived: sum of 2 quarters · filed 2012-04-26 | -$629.00M derived: sum of 3 quarters · filed 2012-04-26 | -$604.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-12-31 | -$763.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$656.00M derived: sum of 2 quarters · filed 2012-02-17 | -$631.00M derived: sum of 3 quarters · filed 2012-07-25 | -$674.00M 10-K · filed 2012-02-17 |
| 2011-09-30 | $107.00M 10-Q · filed 2011-10-27 | $132.00M derived: sum of 2 quarters · filed 2012-07-25 | $89.00M 10-Q · filed 2011-10-27 | $52.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-06-30 | $25.00M 10-Q · filed 2012-07-25 | -$18.00M 10-Q · filed 2012-07-25 | -$55.00M derived: sum of 3 quarters · filed 2012-07-25 | -$89.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-03-31 | -$43.00M 10-Q · filed 2012-04-26 | -$80.00M derived: sum of 2 quarters · filed 2012-04-26 | -$114.00M derived: sum of 3 quarters · filed 2012-04-26 | $11.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2010-12-31 | -$37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$71.00M derived: sum of 2 quarters · filed 2012-02-17 | $54.00M derived: sum of 3 quarters · filed 2012-02-17 | $170.00M 10-K · filed 2012-02-17 |
| 2010-09-30 | -$34.00M 10-Q · filed 2011-10-27 | $91.00M derived: sum of 2 quarters · filed 2011-10-27 | $207.00M 10-Q · filed 2011-10-27 | -$116.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $125.00M 10-Q · filed 2011-07-28 | $241.00M 10-Q · filed 2011-07-28 | -$82.00M derived: sum of 3 quarters · filed 2012-02-17 | -$45.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $116.00M 10-Q · filed 2011-04-28 | -$207.00M derived: sum of 2 quarters · filed 2012-02-17 | -$170.00M derived: sum of 3 quarters · filed 2012-02-17 | $180.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | -$323.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$286.00M derived: sum of 2 quarters · filed 2012-02-17 | $64.00M derived: sum of 3 quarters · filed 2012-02-17 | $178.00M 10-K · filed 2012-02-17 |
| 2009-09-30 | $37.00M 10-Q · filed 2010-10-26 | $387.00M derived: sum of 2 quarters · filed 2010-10-26 | $501.00M 10-Q · filed 2010-10-26 | -$865.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | $350.00M 10-Q · filed 2010-07-22 | $464.00M 10-Q · filed 2010-07-22 | -$902.00M derived: sum of 3 quarters · filed 2011-02-18 | -$743.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | $114.00M 10-Q · filed 2010-04-29 | -$1.25B derived: sum of 2 quarters · filed 2011-02-18 | -$1.09B derived: sum of 3 quarters · filed 2011-02-18 | -$1.06B derived: sum of 4 quarters · filed 2011-02-18 |
| 2008-12-31 | -$1.37B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | -$1.21B derived: sum of 2 quarters · filed 2011-02-18 | -$1.18B derived: sum of 3 quarters · filed 2011-02-18 | -$1.26B 10-K · filed 2011-02-18 |
| 2008-09-30 | $159.00M 10-Q · filed 2009-10-22 | $188.00M derived: sum of 2 quarters · filed 2009-10-22 | $108.00M 10-Q · filed 2009-10-22 | |
| 2008-06-30 | $29.00M 10-Q · filed 2009-07-23 | -$51.00M 10-Q · filed 2009-07-23 | ||
| 2007-12-31 | $184.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |